A Study of HS-10501 Tablets in Healthy Subjects - Trial NCT06359600
Access comprehensive clinical trial information for NCT06359600 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 84 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Mar 14, 2024
Jun 30, 2025
Primary Outcome
Incidence and severity of adverse events(AE) , serious AEs and AE leading to withdrawal from treatment.,Number of participants with clinically significant abnormalities in lab tests,Number of participants with clinically significant change from baseline in vital signs,Change from baseline in Electrocardiogram (ECG)
Summary
The purpose of this study is to evaluate the safety, tolerability, Pharmacokinetics and
 Pharmacodynamics of single dose and multiple dose of HS-10501 tables in healthy subjects.
 This is the first clinical study of HS-10501 tables. This study has 2 parts. Parts A involve
 a single dose of HS-10501 tables or placebo and will last about 8 days. Also, this part will
 also further explore the food effect. Parts B involve multiple doses of HS-10501 tables or
 placebo and will last about 4 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06359600
Non-Device Trial